Mink Therapeutics Valuation
| INKT Stock | USD 0.72 0.03 4.35% |
Mink Therapeutics is undervalued. Mink Therapeutics secures a last-minute Real Value of $2.6 per share. The latest price of the firm is $0.72. Our model forecasts the value of Mink Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 74.64 %, current valuation of 26.92 M, and Return On Equity of -12.39 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mink Therapeutics' valuation include:
Price Book 10.0516 | Enterprise Value 26.9 M | Enterprise Value Ebitda (3.67) |
Undervalued
Today
Please note that Mink Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Mink Therapeutics is based on 3 months time horizon. Increasing Mink Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Mink Therapeutics' intrinsic value may or may not be the same as its current market price of 0.72, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.72 | Real 2.6 | Target 8.33 | Hype 0.72 | Naive 0.68 |
The intrinsic value of Mink Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mink Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mink Therapeutics helps investors to forecast how Mink stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mink Therapeutics more accurately as focusing exclusively on Mink Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mink Therapeutics' intrinsic value based on its ongoing forecasts of Mink Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mink Therapeutics' closest peers.
Mink Therapeutics Cash |
|
Mink Valuation Trend
Mink Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Mink Therapeutics' financial worth over time. Using both Mink Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Mink Therapeutics Total Value Analysis
Mink Therapeutics is currently forecasted to have valuation of 26.92 M with market capitalization of 28.63 M, debt of 22.61 M, and cash on hands of 29.85 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mink Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.92 M | 28.63 M | 22.61 M | 29.85 M |
Mink Therapeutics Asset Utilization
One of the ways to look at asset utilization of Mink is to check how much profit was generated for every dollar of assets it reports. Mink Therapeutics secures a negative usage of assets of -0.97 %, losing $0.009725 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Mink Therapeutics shows how discouraging it operates for each dollar spent on its assets.Mink Therapeutics Ownership Allocation
Mink Therapeutics maintains a total of 39.55 Million outstanding shares. Mink Therapeutics secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 74.64 % of Mink Therapeutics outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Mink Therapeutics Profitability Analysis
Net Loss for the year was (22.46 M) with profit before overhead, payroll, taxes, and interest of 0.About Mink Therapeutics Valuation
The stock valuation mechanism determines Mink Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Mink Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mink Therapeutics. We calculate exposure to Mink Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mink Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -204.6 K | -214.8 K | |
| Pretax Profit Margin | (0.01) | (0.01) | |
| Operating Profit Margin | (0.01) | (0.01) | |
| Net Loss | (0.01) | (0.01) | |
| Gross Profit Margin | (9.40) | (9.87) |
Mink Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Mink Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 34.4 M |
Mink Therapeutics Current Valuation Indicators
Mink Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Mink Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mink Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mink Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mink Therapeutics' worth.Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.